1. Home
  2. KNSA vs BFH Comparison

KNSA vs BFH Comparison

Compare KNSA & BFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • BFH
  • Stock Information
  • Founded
  • KNSA 2015
  • BFH 1996
  • Country
  • KNSA United Kingdom
  • BFH United States
  • Employees
  • KNSA N/A
  • BFH N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • BFH Business Services
  • Sector
  • KNSA Health Care
  • BFH Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • BFH Nasdaq
  • Market Cap
  • KNSA 2.6B
  • BFH 2.8B
  • IPO Year
  • KNSA 2018
  • BFH N/A
  • Fundamental
  • Price
  • KNSA $38.36
  • BFH $63.40
  • Analyst Decision
  • KNSA Strong Buy
  • BFH Hold
  • Analyst Count
  • KNSA 7
  • BFH 15
  • Target Price
  • KNSA $49.71
  • BFH $65.29
  • AVG Volume (30 Days)
  • KNSA 546.2K
  • BFH 847.7K
  • Earning Date
  • KNSA 10-28-2025
  • BFH 10-23-2025
  • Dividend Yield
  • KNSA N/A
  • BFH 1.45%
  • EPS Growth
  • KNSA N/A
  • BFH 55.00
  • EPS
  • KNSA 0.47
  • BFH 9.68
  • Revenue
  • KNSA $597,973,000.00
  • BFH $2,509,000,000.00
  • Revenue This Year
  • KNSA $62.63
  • BFH $59.03
  • Revenue Next Year
  • KNSA $29.93
  • BFH $3.92
  • P/E Ratio
  • KNSA $82.19
  • BFH $6.51
  • Revenue Growth
  • KNSA 55.68
  • BFH 1.70
  • 52 Week Low
  • KNSA $17.82
  • BFH $38.21
  • 52 Week High
  • KNSA $42.05
  • BFH $68.01
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 52.71
  • BFH 55.18
  • Support Level
  • KNSA $36.56
  • BFH $61.75
  • Resistance Level
  • KNSA $39.66
  • BFH $64.59
  • Average True Range (ATR)
  • KNSA 1.58
  • BFH 2.18
  • MACD
  • KNSA -0.13
  • BFH 0.13
  • Stochastic Oscillator
  • KNSA 50.78
  • BFH 47.43

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About BFH Bread Financial Holdings Inc.

Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.

Share on Social Networks: